Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Palomar Medical Technologies

This article was originally published in The Gray Sheet

Executive Summary

Laser hair removal device firm's planned recapitalization includes a one-for-seven reverse stock split. At an April 21 meeting shareholders also approved the sale of the firm's Star Medical Technologies semiconductor laser subsidiary to Coherent for $65 mil. in cash and an ongoing 7.5% royalty. Palomar owns 82% of Star and anticipates a net gain of about $49 mil. before taxes. Closing of the deal, announced in December, is expected "shortly" ("The Gray Sheet" Dec. 14, 1998, p. 8)

You may also be interested in...



Palomar/Laserscope

Palomar grants Laserscope a non-exclusive 7.5% royalty-bearing sublicense to patents in the field of laser hair removal, including U.S. Patent No. 5,595,568 "Permanent Hair Removal Using Optical Pulses," and No. 5,735,844 entitled "Hair Removal Using Optical Pulses." Palomar previously granted a 7.5% sublicense for the same patents to Coherent (1"The Gray Sheet" May 3, 1999, p. 20)

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel